An observational study in Pregnancy, sponsored by Fertility Specialists of Houston. Status unknown at 1 site in United States. Open to female participants aged 20 Years to 39 Years. Per ClinicalTrials.gov, last updated 2012-03-09.
Sponsored by Fertility Specialists of Houston · Observational
Human fallopian tube secretes high concentration of prostacyclin. Fallopian tube is the site for early embryo development. The effect of prostacyclin on human early embryo development is waiting to be clarified. The study hypothesis is prostacyclin can enhance early embryo development.
Huang et al, found that human fallopian tube expresses prostacyclin synthetase and cyclooxygenase. These enzyme systems synthesize abundant prostacyclin (PGI2). In the fallopian tube PGI2 causes smooth muscle relaxation, possibly facilitating tubal transport of gametes and embryos. Huang et al reported that addition of the PGI2 analogue Iloprost to embryo culture media significantly enhanced mouse embryo development to the blastocyst and complete hatched stages. The implantation and live birth rates of Iloprost cultured embryos were significantly better than non-Iloprost embryos in the mouse model. The mean weights of fetal mice were not significant different from control group. There was no teratogenic effect observed.
In a previously presented study, the investigators cultured donated frozen human zygotes in culture media with and without the addition of Iloprost. The Iloprost treated embryos showed significantly better growth rate and morphology, as determined by the size, and grading of the trophectoderm and inner cell mass.
Iloprost is FDA approved for the treatment of pulmonary hypertension. It has a significantly longer half-life than native PGI2. Iloprost is a class C pregnancy drug and has not been associated with teratogenic effects. This study intends to expand the usage of Iloprost to culture embryos.
This is the only study on the registry with Fertility Specialists of Houston as lead sponsor.
Counted across the registry records on this site, refreshed daily.
ART cases with age \< 40 and without pre-implantation genetic diagnosis
Exclusion Criteria:
This is the study group with 1 uM Iloprost.
Drug: Iloprost
This is the control group with vehicle (normal saline) only.
Other: normal saline
supplement in culture medium during culture in the lab. The concentration is 1 uM.
Also known as: Ilomedin
Supplement with vehicle only no Iloprost.
Presence of embryo sac in uterus under ultrasound
The competency of embryo is determined by its ability to implant into endometirum.
Time frame: 5 weeks after embryo transfer
The delivery outcome is the secondary outcome measured.
The live birth and the weight and length of baby is examined.
Time frame: 10 months after embryo transfer
This study is status unknown, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.